期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 57, 期 11, 页码 4466-4486出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm4014746
关键词
-
11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is the enzyme primarily responsible for the regulation of intracellular cortisol levels. Inhibition of 11 beta-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Emerging literature also supports a potential role in the treatment of other unmet medical needs including Alzheimer's disease, vascular inflammation, cardiovascular disease, and glaucoma. The aim of this article is to review the medicinal chemistry literature around small molecule approaches to developing synthetic inhibitors of 11 beta-HSD1 and to highlight key compounds that have resulted from the efforts of both industrial and academic groups. The reported data from 11 beta-HSD1 inhibitors that have progressed into the clinic are summarized followed by a perspective from the authors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据